NVCT Latest Press Releases

-- July 23, 2026 --

Correction: (Title Correction) Nuvectis Announces Marketing Approval of Ciprocopan (NXP100) in China for the Treatment of Patients with PNH Previously Untreated with Complement Inhibitors Globe Newswire 9:00 AM

Ciprocopan (NXP100) Receives Marketing Approval in China for the Treatment of Patients with PNH Previously Untreated with Complement Inhibitors Globe Newswire 7:30 AM

-- June 29, 2026 --

Nuvectis Pharma Announces Pricing of $100 Million Public Offering of Common Stock Globe Newswire 10:30 PM

Nuvectis Pharma Announces Proposed Public Offering of Common Stock Globe Newswire 4:01 PM

-- June 22, 2026 --

Nuvectis Announces Strategic Portfolio Expansion via License Agreement for Ex-China Rights with Haisco Pharmaceutical Group for Two Potentially Best-In Class Clinical-Stage Compounds Globe Newswire 7:30 AM

-- May 14, 2026 --

Nuvectis Pharma, Inc. To Participate in the H.C. Wainwright 4th Annual BioConnect Investor Conference at NASDAQ Globe Newswire 7:30 AM

-- May 5, 2026 --

Nuvectis Pharma, Inc. Reports First Quarter 2026 Financial Results and Business Highlights Globe Newswire 7:30 AM

-- March 31, 2026 --

Nuvectis Pharma Announces Upcoming Presentations for NXP900 at the 2026 American Association for Cancer Research Meeting Globe Newswire 8:00 AM

Market Data Delayed 15 Minutes

Questions? Feedback?Olark live chat software